Grant Summary: Transdisciplinary Translational Team Grant: Moving Cancer Genomics Into Clinical Care

Our study identified four key gaps and potentials ways to address those gaps. These gaps pertain to the following areas:

Roundtable key findings and conclusions:

Clinical adoption of cancer germline testing and tumor sequencing proliferated ahead of formal payer coverage/reimbursement; it varies across settings and geographies and must be studied to compare with guidelines and payer coverage / reimbursement. Of note, payers are interested in not only “premature” or “over”- utilization of genetic panels, but also in under-utilization, for specific indications and patient subgroups.
Of specific research interest are the topics of community vs. academic adoption, and variation across physician categories
New clinical trial designs are incurring considerable research funding, but may not fit the payer evidence assessment approaches and coverage decision frameworks. The divide must be examined and approaches to address it must be researched and developed.
A registry of coverage / reimbursement of genetic technologies could be a valuable tool for providers, researchers, and ultimately patients.